Incidence of psoriatic arthritis in Iraqi psoriatic patients according to serological tests

Authors

  • Wisal Salman Abd

DOI:

https://doi.org/10.66344/jpad.30.1.2020.1304

Keywords:

psoriastic arthritis, psoriasis, anticcp.

Abstract

The present study was accomplished on 82 patients 52 with psoriasis and 30 with psoriatic arthritis (PsA). Age of incidence was 48 years, 42 were female with mean age 39 years and 40 were male with mean age 42 years. Anti-CCP antibodies were estimated using ELISA technique while rheumatoid factor (RF) and C- reactive protein (CRP) were tested using latex serological methods. Ten (50%) PsA patients was positive with Anti-CCP while 5 (16.7%) patients were positive with RF, 1 cutaneous psoriatic patient (1.9%) had positive Anti-CCP and no patients with cutaneous psoriasis had positive RF. RF can help in distinguishing between RA and psoriasis. Seven (23.3%) PsA patients were followed-up for Anti-CCP antibodies for 1 year every 3 months. There was an observed increased in levels of Anti-CCP antibodies. It could be concluded that Anti-CCP antibody is a good indicator for the follow up study and progression of PsA.

Downloads

Published

2020-08-07

How to Cite

1.
Abd WS. Incidence of psoriatic arthritis in Iraqi psoriatic patients according to serological tests. J Pak Assoc Dermatol [Internet]. 2020Aug.7 [cited 2026Apr.15];30(1):72-80. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/1304

Issue

Vol. 30 No. 1 (2020): January - March

Section

Original Articles

License

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.